Renerve Receives Positive FDA Feedback on NervAlign Nerve Guide Matrix
Key points
- Positive feedback from FDA on NervAlign Nerve Guide Matrix
- FDA supports proposed preclinical evaluation model
- Clear guidance on control groups and testing expectations
- Feedback to inform final testing plan and regulatory submission
Full summary
Renerve Ltd, an Australian medical device company focused on peripheral nerve repair, announced that it received positive feedback from the US Food and Drug Administration (FDA) following a pre-submission meeting for its NervAlign Nerve Guide Matrix (NGM) program. The FDA supported Renerve's proposed preclinical evaluation model and provided guidance on control groups and biochemical and biophysical testing expectations. This feedback will inform the company's final testing plan and regulatory submission package. Renerve is continuing production of NGM with its contract manufacturing organization (CMO) and will update the market on the progress of the planned submission.
Outlook
Renerve is expected to finalize its testing plan and submit regulatory data based on FDA feedback, aiming for clearance ahead of marketing approval.
Summary generated by a large language model. Please interpret with care.